title: Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.
abstract: Evaluation of [18F]fluoromisonidazole ([18F]FMISO)-positron emission tomography (PET) imaging as a metric for evaluating early response to trastuzumab therapy with histological validation in a murine model of HER2+ breast cancer.
  
  
  
  Mice with BT474, HER2+ tumors, were imaged with [18F]FMISO-PET during trastuzumab therapy. Pimonidazole staining was used to confirm hypoxia from imaging.
  
  
  
  [18F]FMISO-PET indicated significant decreases in hypoxia beginning on day 3 (P < 0.01) prior to changes in tumor size. These results were confirmed with pimonidazole staining on day 7 (P < 0.01); additionally, there was a significant positive linear correlation between histology and PET imaging (r2= 0.85).
  
  
  
  [18F]FMISO-PET is a clinically relevant modality which provides the opportunity to (1) predict response to HER2+ therapy before changes in tumor size and (2) identify decreases in hypoxia which has the potential to guide subsequent therapy.
authors: Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, 1912 Speedway, Austin, TX, 78712, USA. anna.sorace@austin.utexas.edu.
authors: Anna G
authors: AG
authors: Sorace
authors: Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
authors: Anum K
authors: AK
authors: Syed
authors: Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.|Institute for Computational and Engineering Sciences, The University of Texas at Austin, Austin, TX, USA.
authors: Stephanie L
authors: SL
authors: Barnes
authors: Division of Imaging Research, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
authors: C Chad
authors: CC
authors: Quarles
authors: Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA.
authors: Violeta
authors: V
authors: Sanchez
authors: Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
authors: Hakmook
authors: H
authors: Kang
authors: Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, 1912 Speedway, Austin, TX, 78712, USA.|Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.|Institute for Computational and Engineering Sciences, The University of Texas at Austin, Austin, TX, USA.
authors: Thomas E
authors: TE
authors: Yankeelov
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D005455:Fluorescent Antibody Technique; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000473:pathology*; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000737:chemistry; D009593:Nitroimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D049268:Positron-Emission Tomography / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab / Q000494:pharmacology / Q000627:therapeutic use*; D047368:Tumor Burden; D000072258:Tumor Hypoxia / Q000187:drug effects
chemical_list: D014408:Biomarkers, Tumor; D008920:Misonidazole; D009593:Nitroimidazoles; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C031843:fluoromisonidazole; C033815:pimonidazole
keywords: BT474; FMISO; Herceptin; Misonidazole; Oxygenation; Pimonidazole; Vascular maturation